These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 36159944)
1. Availability of opioid agonist treatment and critical incidents in Forensic Clinics for Dependency Diseases in Germany. Reiners S; Opitz-Welke A; Konrad N; Voulgaris A Front Psychiatry; 2022; 13():961549. PubMed ID: 36159944 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of Opioid Dependence and Opioid Agonist Treatment in the Berlin Custodial Setting: A Cross-Sectional Study. von Bernuth K; Seidel P; Krebs J; Lehmann M; Neumann B; Konrad N; Opitz-Welke A Front Psychiatry; 2020; 11():794. PubMed ID: 32903474 [TBL] [Abstract][Full Text] [Related]
3. Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study. Bech AB; Clausen T; Waal H; Šaltytė Benth J; Skeie I BMC Health Serv Res; 2019 Jul; 19(1):440. PubMed ID: 31266495 [TBL] [Abstract][Full Text] [Related]
4. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394 [TBL] [Abstract][Full Text] [Related]
6. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study. Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083 [TBL] [Abstract][Full Text] [Related]
7. Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions. Tran AD; Chen R; Nielsen S; Zahra E; Degenhardt L; Santo T; Farrell M; Larance B Int J Drug Policy; 2022 Jan; 99():103472. PubMed ID: 34649203 [TBL] [Abstract][Full Text] [Related]
8. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine. Morozova O; Dvoriak S; Pykalo I; Altice FL Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537 [TBL] [Abstract][Full Text] [Related]
9. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors. Oliva EM; Harris AH; Trafton JA; Gordon AJ Drug Alcohol Depend; 2012 May; 122(3):241-6. PubMed ID: 22115887 [TBL] [Abstract][Full Text] [Related]
10. Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada. Farrell MacDonald S; Russell C; Beauchamp T; Derkzen D; Fischer B Int J Drug Policy; 2022 Feb; 100():103480. PubMed ID: 34656817 [TBL] [Abstract][Full Text] [Related]
11. Voluntary patient safety incidents reporting in forensic psychiatry-What do the reports tell us? Kuosmanen A; Tiihonen J; Repo-Tiihonen E; Turunen H J Psychiatr Ment Health Nurs; 2022 Feb; 29(1):36-47. PubMed ID: 33548085 [TBL] [Abstract][Full Text] [Related]
12. Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study. Meteliuk A; Galvez S; Fomenko T; Kalandiia H; Iaryi V; Farnum SO; Islam Z; Altice FL; Madden LM J Subst Abuse Treat; 2022 Mar; 134():108619. PubMed ID: 34579978 [TBL] [Abstract][Full Text] [Related]
13. Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters. Bandara S; Kennedy-Hendricks A; Merritt S; Barry CL; Saloner B Addiction; 2021 Dec; 116(12):3473-3481. PubMed ID: 33999458 [TBL] [Abstract][Full Text] [Related]
14. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia. Geddes L; Iversen J; Wand H; Maher L Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931 [TBL] [Abstract][Full Text] [Related]
15. Incidents of aggression in German psychiatric hospitals: Is there an increase? Eisele F; Flammer E; Steinert T PLoS One; 2021; 16(1):e0245090. PubMed ID: 33400702 [TBL] [Abstract][Full Text] [Related]
16. Evidence-based treatment for opioid use disorder is widely unavailable and often discouraged by providers of residential substance use services in North Carolina. Carroll JJ; Dasgupta N; Ostrach B; El-Sabawi T; Dixon S; Morrissey B; Saucier R J Subst Use Addict Treat; 2024 Dec; 167():209474. PubMed ID: 39179208 [TBL] [Abstract][Full Text] [Related]
17. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey. Kouyoumdjian FG; Patel A; To MJ; Kiefer L; Regenstreif L PLoS One; 2018; 13(2):e0192431. PubMed ID: 29447177 [TBL] [Abstract][Full Text] [Related]
18. [Opioid agonist therapy and the German Narcotic Drugs Prescription Ordinance from the pharmacist's perspective]. Kuhn S; Lehmann K; Schulte B; Verthein U Z Evid Fortbild Qual Gesundhwes; 2022 Feb; 168():57-64. PubMed ID: 34955439 [TBL] [Abstract][Full Text] [Related]
19. Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy. Kutsa O; Marcus R; Bojko MJ; Zelenev A; Mazhnaya A; Dvoriak S; Filippovych S; Altice FL J Int AIDS Soc; 2016; 19(4 Suppl 3):20897. PubMed ID: 27435717 [TBL] [Abstract][Full Text] [Related]